August 30, 2014 6:36 AM ET

Food and Staples Retailing

Company Overview of BioPharm Asia, Inc.

Company Overview

BioPharm Asia, Inc. engages in the sale of medical products to drug stores, hospitals, neighborhood clinics, and other medicine retail outlets in the People’s Republic of China. Its products include approximately 300 prescription drugs; approximately 1,150 over the counter drugs comprising western medicines and traditional Chinese medicines for the treatment of common diseases; approximately 85 nutritional supplements consisting of healthcare supplements, vitamins, minerals, and dietary products; and various types of drinkable herbal remedies and packages of assorted herbs for making soup, which are used by consumers as health supplements. The company’s other products comprise personal care ...

New Agriculture Development Park

Daquan Village

Tonghua County,  134115

China

1,778 Employees

Phone:

86 43 5521 1803

Key Executives for BioPharm Asia, Inc.

Chief Executive Officer
Age: 51
Chief Financial Officer
Age: 45
Compensation as of Fiscal Year 2014.

BioPharm Asia, Inc. Key Developments

SEC Revokes Registration Of Registered Securities Of Biopharm Asia

An Administrative Law Judge has issued an Order Making Findings and Revoking Registration by Default (Default Order) in Biopharm Asia, Inc., Admin. Proc. File No. 3-15287. The Order Instituting Proceedings alleged that Biopharm Asia, Inc. repeatedly failed to file timely periodic reports while its securities were registered with the Securities and Exchange Commission (SEC). The Default Order finds these allegations to be true and revokes the registration of each class of its registered securities, pursuant to Section 12(j) of the Securities Exchange Act of 1934.

SEC Orders Hearing On Registration Suspension Or Revocation Against Securities Of Biopharm Asia

Securities and Exchange Commission (SEC or the commission) announced the issuance of orders instituting administrative proceedings and notice of hearing pursuant to Section 12(j) of the Securities Exchange Act of 1934 to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Biopharm Asia, Inc for failure to make required periodic filings with the Commission. In the Order, the Division of Enforcement (Division) alleges that the company was delinquent in their required periodic filings with the Commission. In these proceedings, instituted pursuant to Exchange Act Section 12(j), hearings will be scheduled before an Administrative Law Judge. At the hearings, the judge will hear evidence from the Division and company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceedings will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in these proceedings issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioPharm Asia, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.